The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure
Stenver, D.; Jeppesen, L.; Nielsen, B.; Dalsgaard Nielsen, J.; Haedersdal, C.; Mehlsen, J.; Winther, K.
International Journal of Artificial Organs 17(3): 141-145
1994
ISSN/ISBN: 0391-3988 PMID: 8050804 Document Number: 430995
The influence of erythropoietin therapy on platelet function and fibrinolysis was evaluated in 12 anemic hemodialysis patients. Six months of therapy with human erythropoietin (50 to 80 IU/kg initially) raised the hemoglobin level to 10.8 g/dl but did not increase platelet activity in vivo as measured by beta-thromboglobulin or platelet factor 4. There was no change in the platelet aggregation thresholds in vitro for ADP, adrenaline, thrombin or collagen during treatment. Platelet number and volume were also unaffected. Fibrinolytic activity intensified as erythropoietin treatment proceeded, with a fall of euglobulin clot lysis time and rise in the activity of t-PA. PAI-1 levels also showed a downward trend, without reaching significance. Thus erythropoietin treatment in modest doses does not seem to adversely influence the hemostatic system in patients on hemodialysis.